Literature DB >> 27591257

Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells.

Ying Wang1, Ying Cao1, Ashutosh K Mangalam2, Yong Guo3, Reghann G LaFrance-Corey3, Jeffrey D Gamez3, Pascal Aliihnui Atanga3, Benjamin D Clarkson3, Yuebo Zhang4, Enfeng Wang1, Ramcharan Singh Angom1, Kirthica Dutta1, Baoan Ji4, Istvan Pirko3, Claudia F Lucchinetti3, Charles L Howe3, Debabrata Mukhopadhyay5.   

Abstract

Inflammatory response of blood-brain barrier (BBB) endothelial cells plays an important role in pathogenesis of many central nervous system inflammatory diseases, including multiple sclerosis; however, the molecular mechanism mediating BBB endothelial cell inflammatory response remains unclear. In this study, we first observed that knockdown of neuropilin-1 (NRP1), a co-receptor of several structurally diverse ligands, suppressed interferon-γ (IFNγ)-induced C-X-C motif chemokine 10 expression and activation of STAT1 in brain microvascular endothelial cells in a Rac1-dependent manner. Moreover, endothelial-specific NRP1-knockout mice, VECadherin-Cre-ERT2/NRP1flox/flox mice, showed attenuated disease progression during experimental autoimmune encephalomyelitis, a mouse neuroinflammatory disease model. Detailed analysis utilizing histological staining, quantitative PCR, flow cytometry and magnetic resonance imaging demonstrated that deletion of endothelial NRP1 suppressed neuron demyelination, altered lymphocyte infiltration, preserved BBB function and decreased activation of the STAT1-CXCL10 pathway. Furthermore, increased expression of NRP1 was observed in endothelial cells of acute multiple sclerosis lesions. Our data identify a new molecular mechanism of brain microvascular endothelial inflammatory response through NRP1-IFNγ crosstalk that could be a potential target for intervention of endothelial cell dysfunction in neuroinflammatory diseases.
© 2016. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Brain microvascular endothelial cells; Inflammatory response; Interferon-γ; Neuroinflammatory diseases; Neuropilin-1

Mesh:

Substances:

Year:  2016        PMID: 27591257      PMCID: PMC5087664          DOI: 10.1242/jcs.190702

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  64 in total

Review 1.  Blood-brain barrier disruption in multiple sclerosis.

Authors:  Alireza Minagar; J Steven Alexander
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

2.  CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system.

Authors:  Marcus Müller; Sally L Carter; Markus J Hofer; Peter Manders; Daniel R Getts; Meghan T Getts; Angela Dreykluft; Bao Lu; Craig Gerard; Nicholas J C King; Iain L Campbell
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 3.  The epidemiology of multiple sclerosis: insights to disease pathogenesis.

Authors:  Douglas S Goodin
Journal:  Handb Clin Neurol       Date:  2014

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability.

Authors:  Patrice M Becker; Johannes Waltenberger; Robin Yachechko; Tamara Mirzapoiazova; James S K Sham; Chun Geun Lee; Jack A Elias; Alexander D Verin
Journal:  Circ Res       Date:  2005-05-26       Impact factor: 17.367

Review 6.  Immunological functions of the neuropilins and plexins as receptors for semaphorins.

Authors:  Atsushi Kumanogoh; Hitoshi Kikutani
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

7.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

Review 9.  The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

Authors:  Howard L Weiner
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

10.  A requirement for neuropilin-1 in embryonic vessel formation.

Authors:  T Kawasaki; T Kitsukawa; Y Bekku; Y Matsuda; M Sanbo; T Yagi; H Fujisawa
Journal:  Development       Date:  1999-11       Impact factor: 6.868

View more
  19 in total

Review 1.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

2.  Nanomechanical insights: Amyloid beta oligomer-induced senescent brain endothelial cells.

Authors:  Tanmay Kulkarni; Ramcharan Singh Angom; Pritam Das; Santanu Bhattacharya; Debabrata Mukhopadhyay
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-09-09       Impact factor: 3.747

Review 3.  Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health.

Authors:  Richard L Doty
Journal:  Trends Mol Med       Date:  2022-06-20       Impact factor: 15.272

4.  Neuropilin-1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II-induced hypertension.

Authors:  Ying Wang; Enfeng Wang; Yuebo Zhang; Vijay S Madamsetty; Baoan Ji; Derek C Radisky; Joseph P Grande; Sanjay Misra; Debabrata Mukhopadhyay
Journal:  FASEB J       Date:  2018-08-17       Impact factor: 5.191

5.  Depletion of PD-1-positive cells ameliorates autoimmune disease.

Authors:  Peng Zhao; Peng Wang; Shuyun Dong; Zemin Zhou; Yanguang Cao; Hideo Yagita; Xiao He; Song Guo Zheng; Simon J Fisher; Robert S Fujinami; Mingnan Chen
Journal:  Nat Biomed Eng       Date:  2019-03-04       Impact factor: 29.234

Review 6.  Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier?

Authors:  Susan M Burks; Hector Rosas-Hernandez; Manuel Alenjandro Ramirez-Lee; Elvis Cuevas; John C Talpos
Journal:  Brain Behav Immun       Date:  2021-01-04       Impact factor: 7.217

Review 7.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

8.  Bu-Shen-Yi-Sui Capsule, an Herbal Medicine Formula, Promotes Remyelination by Modulating the Molecular Signals via Exosomes in Mice with Experimental Autoimmune Encephalomyelitis.

Authors:  Pei-Yuan Zhao; Jing Ji; Xi-Hong Liu; Hui Zhao; Bin Xue; Liang-Yun Jin; Yong-Ping Fan; Wen-Jing Zhao; Lei Wang
Journal:  Oxid Med Cell Longev       Date:  2020-07-22       Impact factor: 6.543

Review 9.  Interferon-Gamma-Mediated Osteoimmunology.

Authors:  Mengjia Tang; Li Tian; Guojing Luo; Xijie Yu
Journal:  Front Immunol       Date:  2018-06-29       Impact factor: 7.561

10.  Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer.

Authors:  Chen Chen; Rui Zhang; Li Ma; Qi Li; Ya-Ling Zhao; Guan-Jun Zhang; Dong Zhang; Wen-Zhi Li; Sheng Cao; Lin Wang; Zhi-Min Geng
Journal:  J Cell Mol Med       Date:  2020-09-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.